FDA approves pimicotinib for symptomatic tenosynovial giant cell tumor

A new milestone in the treatment of tenosynovial giant cell tumour (TGCT): the US Food and Drug Administration (FDA) has approved pimicotinib (Pimjetmi) for adults with symptomatic TGCT for whom surgery may cause worsening functional limitations or severe complications.

The approval, announced on 10 November 2026, marks an important development for the TGCT community and adds a new treatment option for eligible patients in the United States.

Pimicotinib was developed by Abbisko Therapeutics and is licensed globally to Merck KGaA for commercialisation. Its approval in the US follows previous approvals in China, Canada and Switzerland.

For further information about the approval and its medical details, please visit the official FDA announcement.